Loading…
Please register to continue your trial period!
meRfi Microbiome provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.
Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.
Start your free trial and transform your understanding of the gut microbiota today!
In the context of Gefitinib & Non-small-cell lung cancer (NSCLC) (EGFR m), gefitinib is both FDA‑ and EMA‑approved for Non-small-cell lung cancer (NSCLC) (EGFR m), primarily as first‑line monotherapy in patients with sensitizing HER1/EGFR/ErbB-1 (epidermal growth factor receptor) (MUT) (1, 2, 3, 4).
The randomized clinical phase III treatment trial, identified as UMIN 000006252, demonstrated that while adjuvant gefitinib seemed effective in…